{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T23:27:06Z","timestamp":1773444426149,"version":"3.50.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s10067-023-06794-3","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:02:26Z","timestamp":1697799746000},"page":"3421-3422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring the patient experience in polymyalgia rheumatica"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2671-4784","authenticated-orcid":false,"given":"Georgia K.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3834-2706","authenticated-orcid":false,"given":"Jessica L.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3404-9665","authenticated-orcid":false,"given":"Russell R. C.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"issue":"12","key":"6794_CR1","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/annrheumdis-2018-213883","volume":"77","author":"R Partington","year":"2018","unstructured":"Partington R et al (2018) Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis 77(12):1750\u20131756. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213883","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6794_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.pec.2014.12.013","volume":"98","author":"H Twohig","year":"2015","unstructured":"Twohig H et al (2015) \u201cI suddenly felt I\u2019d aged\u201d: a qualitative study of patient experiences of polymyalgia rheumatica (PMR). Patient Educ Couns 98(5):645\u2013650. https:\/\/doi.org\/10.1016\/j.pec.2014.12.013","journal-title":"Patient Educ Couns"},{"issue":"12","key":"6794_CR3","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1007\/s10067-018-4220-1","volume":"37","author":"S Muller","year":"2018","unstructured":"Muller S et al (2018) Support available for and perceived priorities of people with polymyalgia rheumatica and giant cell arteritis: results of the PMRGCAuk members\u2019 survey 2017. Clin Rheumatol 37(12):3411\u20133418. https:\/\/doi.org\/10.1007\/s10067-018-4220-1","journal-title":"Clin Rheumatol"},{"issue":"6","key":"6794_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s10067-018-04405-0","volume":"38","author":"C Morton","year":"2019","unstructured":"Morton C et al (2019) Examining management and research priorities in patients with polymyalgia rheumatica: a primary care questionnaire survey. Clin Rheumatol 38(6):1767\u20131772. https:\/\/doi.org\/10.1007\/s10067-018-04405-0","journal-title":"Clin Rheumatol"},{"key":"6794_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/OARRR.S213964","volume":"11","author":"E Hoon","year":"2019","unstructured":"Hoon E et al (2019) A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis. Open Access Rheumatol 11:189\u2013198. https:\/\/doi.org\/10.2147\/OARRR.S213964","journal-title":"Open Access Rheumatol"},{"issue":"6","key":"6794_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3899\/jrheum.200248","volume":"48","author":"H Twohig","year":"2021","unstructured":"Twohig H et al (2021) Outcomes measured in polymyalgia rheumatica and measurement properties of instruments considered for the OMERACT core outcome set: a systematic review. J Rheumatol 48(6):883\u2013893. https:\/\/doi.org\/10.3899\/jrheum.200248","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06794-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T07:18:30Z","timestamp":1699687110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06794-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6794"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06794-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"28 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Georgia Harris declares no conflict of interest. Jessica Leung received speaker fees from Novartis. Jessica has participated on the advisory board and paid advisory board fees from Fresenius Kabi. Jessica has participated on the advisory board and paid advisory board fees and speaker fees from Eli Lilly. Jessica has participated on the advisory board and paid advisory board fees and speaker fees from AbbVie. Russell Buchanan declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}